发明名称 |
Regulatory immune cells with enhanced targeted cell death effect |
摘要 |
An isolated immune regulatory cell having an exogenous cell death-inducing moiety attached to a surface thereof is disclosed herein. Additionally, a molecule comprising a cell death-inducing moiety heterologously attached to an immune regulatory cell-specific binding moiety is disclosed herein. Methods of generating and using same as well as pharmaceutical compositions comprising same are also disclosed. |
申请公布号 |
US9624469(B2) |
申请公布日期 |
2017.04.18 |
申请号 |
US201113811374 |
申请日期 |
2011.07.21 |
申请人 |
Cellect Biotherapeutics Ltd. |
发明人 |
Yarkoni Shai;Askenasy Nadir |
分类号 |
A01N63/00;C12N5/0783;A61K35/16;A61K35/17;A61K35/26;A61K39/00;C12N5/00 |
主分类号 |
A01N63/00 |
代理机构 |
Wood, Phillips, Katz, Clark & Mortimer |
代理人 |
Wood, Phillips, Katz, Clark & Mortimer |
主权项 |
1. A method of treating a medical condition selected from the group consisting of: diabetes mellitus type I, inflammatory bowel disease, graft versus host disease and transplant rejection in a subject in need thereof, the method comprising: a) recombinantly expressing or immobilizing FasL ex vivo on the surface of isolated CD4+CD25+ regulatory T cells, thereby generating isolated CD4+CD25+ regulatory T cells overexpressing FasL; b) administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising said isolated CD4+CD25+ regulatory T cells overexpressing FasL, thereby treating the medical condition. |
地址 |
IL |